Core Viewpoint - The stock of Baiaosaitu-B (02315) surged over 12%, reaching a new high of 35.86 HKD, driven by the announcement of its upcoming listing on the Shanghai Stock Exchange's STAR Market in December 2025 [1] Group 1: Stock Performance - Baiaosaitu-B's stock increased by 12.52%, trading at 35.76 HKD with a transaction volume of 11.6962 million HKD [1] Group 2: Company Announcement - Baiaosaitu announced that its ordinary shares will be listed on the STAR Market on December 10, 2025, following approval from the Shanghai Stock Exchange [1] Group 3: Analyst Insights - Huafu Securities highlighted that the company's antibody licensing is beginning to yield results, driving significant performance growth [1] - The company is recognized for its high growth potential and strong barriers to entry, with a solid foundation in preclinical animal and pharmacological evaluations [1] - The antibody development business is entering a phase of performance realization, complemented by a promising pipeline of potential new drugs, leading to an initial "Buy" rating [1]
百奥赛图-B涨超12%创新高 即将登陆A股科创板 公司千鼠万抗开始兑现